DCLT- Data Call Technologies
DCLT is due for a bounce. This is an under the radar real time data technology company that has a very small float and is current. These type of stocks have a history of 1,000-3,000% gains. This is a buy low sell high play.
CDTX-Cidara Therapeutics, Inc.
CDTX is a biotech company that specializes in treatment of infections. Cidara is working on advancing its echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial, for the treatment of candidemia and invasive candidiasis and continues to discuss with regulatory authorities its plans for the design and initiation of a second Phase 3 trial in the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation. They have a presentation coming up in at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). April 13th is the date we are watching with this stock. We believe the stock price sees nice momentum going into the phase 3 results. After the results come out these are normally a gamble so we usually take profit before to manage risk.
CNAT is a biotech company with the focus on treating and curing liver diseases. It currently has two fda trials Emricasan, an Oral Caspase Inhibitor and Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis (ENCORE-LF).
The dates we are watching are: Late breaker at EASL April 13, 2019, 4:00 p.m. CEST. 48-week liver function data due mid-2019.
BioTime is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. They are currently working on Dry age-related macular degeneration. We are expecting an update April 30th at the Ophthalmology Annual Meeting.
Disclaimer: I own shares of DCLT,CNAT, BTX and CDTX. I reserve the right to buy or sell at anytime. I view these stocks as swing trades only. Everything on this page is not advice and is just an opinion. Make your own buying and selling decisions. Please do your own due diligence.